A pharmaceutical composition containing inter-alpha-trypsin inhibitor heavy chain h4 protein and its use for treating pulmonary diseases

Abstract

This invention discloses a pharmaceutical composition containing the α-trypsin inhibitor heavy chain H4 protein and its use in treating lung diseases. The pharmaceutical composition of this invention can promote alveolar epithelial regeneration, repair alveolar structure, and restore gas exchange function by maintaining the survival of alveolar type II epithelial cells and promoting their differentiation into alveolar type I epithelial cells. It is suitable for treating lung diseases related to alveolar damage, inflammatory response, or structural remodeling, including acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis. By regulating the survival and differentiation of alveolar epithelial cells, the pharmaceutical composition of this invention provides a novel therapeutic strategy for the repair and functional recovery of lung diseases.

Claims

1. Use of an ITIH4 protein in the preparation of a pharmaceutical composition for promoting lung tissue regeneration, wherein the pharmaceutical composition comprises an effective amount of the ITIH4 protein and one or more pharmaceutically acceptable carriers, diluents or excipients.

2. As claimed in claim 1, wherein the promotion of lung tissue regeneration is achieved by maintaining the survival of alveolar type II epithelial cells and promoting the differentiation of alveolar type II epithelial cells into alveolar type I epithelial cells.

3. The use as claimed in claim 1, wherein the pharmaceutical composition is used to repair alveolar structure, restore gas exchange function, and alleviate lung diseases caused by alveolar damage or inflammation.

4. As claimed in claim 3, wherein the lung disease includes acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis.

5. As claimed in claim 1, wherein the carrier comprises an aqueous solution, a buffer solution, an emulsion, a gel, or a microparticle suspension.

6. As claimed in claim 1, wherein the dosage form of the pharmaceutical composition includes an inhaled aerosol, a dry powder inhaler, an endotracheal instillation, a nasal spray, or an intravenous injection.

7. As claimed in claim 1, wherein the effective amount of the ITIH4 protein is from 0.001 mg to 1 mg per kilogram of body weight per individual.

8. As claimed in claim 1, wherein the effective amount of the ITIH4 protein is from 0.01 mg to 0.1 mg per kilogram of body weight per individual.

9. As claimed in claim 1, wherein the effective amount of the ITIH4 protein is 0.02 mg to 0.05 mg per kilogram of body weight per individual.

Images